These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8197932)

  • 1. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
    Oosterlinck W; Mast P
    Acta Urol Belg; 1994 Apr; 62(1):67-71. PubMed ID: 8197932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
    Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
    Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of current status of total androgen deprivation in metastasized prostate cancer.
    Debruyne FM; Witjes WP
    Eur Urol; 1993; 24 Suppl 2():67-71. PubMed ID: 8262129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Total androgen blockade for prostate cancer].
    Kagebayashi Y; Ozono S; Takashima K; Yoshikawa M; Hayashi Y; Kaneko Y; Maruyama Y; Hirao Y; Okajima E
    Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyproterone acetate in comparison to flutamide on the ventral prostate of adult male castrated Copenhagen-Fisher rats and on Dunning R-3327 H tumors.
    Donn F; Becker H; Klosterhalfen H; Klein H
    Andrologia; 1989; 21(5):462-7. PubMed ID: 2530921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
    Bolla M
    Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
    Geller J
    J Androl; 1991; 12(6):364-71. PubMed ID: 1769904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen blockade in prostate cancer.
    Labrie F; Candas B
    Lancet; 2000 Jul; 356(9226):341-2. PubMed ID: 11071217
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiation of LHRH monotherapy for prostate cancer.
    Milsted RA
    Prog Clin Biol Res; 1989; 303():69-74. PubMed ID: 2528742
    [No Abstract]   [Full Text] [Related]  

  • 20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.